(DTIL) Precision BioSciences - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74019P2074
DTIL: Gene editing therapies, Genome editing platform
Precision BioSciences Inc (NASDAQ:DTIL) is a pioneering gene editing company specializing in in vivo therapies. Utilizing their proprietary ARCUS platform, they focus on precise genome editing, enabling targeted DNA modifications for various therapeutic applications. Their pipeline includes treatments for chronic hepatitis B, primary mitochondrial myopathy, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and ornithine transcarbamylase deficiency. Strategic collaborations with industry leaders like Caribou Biosciences, Eli Lilly, Cellectis, iECURE, Duke University, and Novartis underscore their commitment to advancing gene editing technologies. Incorporated in 2006 and headquartered in Durham, NC, the company is at the forefront of innovative medical solutions.
The companys therapeutic developments include PBGENE-HBV, designed to eliminate hepatitis B virus DNA, and PBGENE-PMM, targeting mitochondrial myopathy. Additional candidates address severe genetic disorders, showcasing a diverse approach to tackling rare and prevalent diseases. These initiatives are supported by partnerships that enhance research and commercialization efforts, positioning Precision BioSciences as a key player in the biotech industry.
Additional Sources for DTIL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DTIL Stock Overview
| Market Cap in USD | 61m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2019-03-28 |
DTIL Stock Ratings
| Growth Rating | -91.2 |
| Fundamental | 16.1 |
| Dividend Rating | 0.0 |
| Rel. Strength | -47.9 |
| Analysts | 4.6/5 |
| Fair Price Momentum | 2.42 USD |
| Fair Price DCF | - |
DTIL Dividends
No Dividends PaidDTIL Growth Ratios
| Growth Correlation 3m | 0% |
| Growth Correlation 12m | -88.7% |
| Growth Correlation 5y | -93.4% |
| CAGR 5y | -53.18% |
| CAGR/Max DD 5y | -0.54 |
| Sharpe Ratio 12m | -1.53 |
| Alpha | -59.43 |
| Beta | 0.144 |
| Volatility | 94.42% |
| Current Volume | 69.7k |
| Average Volume 20d | 101.2k |
As of May 09, 2025, the stock is trading at USD 5.15 with a total of 69,676 shares traded.
Over the past week, the price has changed by -9.97%, over one month by +11.47%, over three months by +7.52% and over the past year by -54.30%.
Neither. Based on ValueRay Fundamental Analyses, Precision BioSciences is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 16.10 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DTIL as of May 2025 is 2.42. This means that DTIL is currently overvalued and has a potential downside of -53.01%.
Precision BioSciences has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy DTIL.
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DTIL Precision BioSciences will be worth about 2.6 in May 2026. The stock is currently trading at 5.15. This means that the stock has a potential downside of -49.32%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 29.4 | 470.9% |
| Analysts Target Price | 29.4 | 470.9% |
| ValueRay Target Price | 2.6 | -49.3% |